Table 1. Demographic, behavioral and clinical characteristics at the start of ART for patients followed at the Evandro Chagas Clinical Research Institute (IPEC) and the Johns Hopkins AIDS Services.
| IPEC | Johns Hopkins | Total | |
| Patients | 1822 | 1294 | 3116 |
| Age a | |||
| Median (IQR) | 36 (30,44) | 42 (36,48) | 39 (32,46) |
| <30 years | 421 (23.1) | 130 (10) | 551 (17.7) |
| 30–39 years | 684 (37.5) | 377 (29.1) | 1061 (34.1) |
| 40–49 years | 490 (26.9) | 504 (38.9) | 994 (31.9) |
| >50 years | 227 (12.5) | 283 (21.9) | 510 (16.4) |
| Gender | |||
| Female | 573 (31.4) | 469 (36.2) | 1042 (33.4) |
| Male | 1249 (68.6) | 825 (63.8) | 2074 (66.6) |
| Race/ethnicity | |||
| White | 905 (49.7) | 238 (18.4) | 1143 (36.7) |
| Non-white | 917 (50.3) | 1056 (81.6) | 1973 (63.3) |
| HIV risk exposure category b | |||
| Not IDU | 1807 (99.2) | 904 (69.9) | 2711 (87) |
| IDU | 15 (0.8) | 390 (30.1) | 405 (13) |
| Pre-treatment CD4 T-cell count c | |||
| Median (IQR) | 199 (74,292.8) | 184 (51.2,314) | 194 (65,299) |
| <100 | 479 (26.3) | 340 (26.3) | 819 (26.3) |
| 100–199 | 306 (16.8) | 186 (14.4) | 492 (15.8) |
| 200–349 | 556 (30.5) | 273 (21.1) | 829 (26.6) |
| > = 350 | 221 (12.1) | 199 (15.4) | 420 (13.5) |
| Missing | 260 (14.3) | 296 (22.9) | 556 (17.8) |
| Nadir CD4 T-cell count | |||
| Median (IQR) | 190 (71.5,278) | 158 (32.8,280) | 179 (53,279) |
| <50 | 311 (17.1) | 346 (26.7) | 657 (21.1) |
| 50–199 | 528 (29.0) | 327 (25.3) | 855 (27.4) |
| 200–349 | 606 (33.3) | 312 (24.1) | 918 (29.5) |
| > = 350 | 170 (9.3) | 159 (12.3) | 329 (10.6) |
| Missing | 207 (11.4) | 150 (11.6) | 357 (11.5) |
| Pre-treatment HIV viral load c | |||
| ≤400 | 30 (1.6) | 120 (9.3) | 150 (4.8) |
| 401–3000 | 59 (3.2) | 55 (4.3) | 114 (3.7) |
| 3001–10000 | 117 (6.4) | 80 (6.2) | 197 (6.3) |
| 10001–100000 | 527 (28.9) | 395 (30.5) | 922 (29.6) |
| >100000 | 625 (34.3) | 382 (29.5) | 1007 (32.3) |
| Missing | 464 (25.5) | 262 (20.2) | 726 (23.3) |
| Initial ART regimen d | |||
| NNRTI | 1280 (70.3) | 679 (52.5) | 1959 (62.9) |
| PI | 505 (27.7) | 587 (45.4) | 1092 (35) |
| ADI at start of ART e | |||
| No | 1061 (58.2) | 1019 (78.7) | 2080 (66.8) |
| Yes | 761 (41.8) | 275 (21.3) | 1036 (33.2) |
| Hepatitis B co-infection f | |||
| No | 1750 (96) | 1231 (95.1) | 2981 (95.7) |
| Yes | 72 (4.0) | 63 (4.9) | 135 (4.3) |
| Hepatitis C co-infection f | |||
| No | 1746 (95.8) | 892 (68.9) | 2638 (84.7) |
| Yes | 76 (4.2) | 402 (31.1) | 478 (15.3) |
HIV: human immunodeficiency virus, ART: antiretroviral therapy, ADI: AIDS defining illness.
a
Age at the start of ART.
b
Reported mode of HIV risk exposure was categorized injection drug users (IDU) and not IDU
c
Pre-treatment CD4+ cell count and HIV RNA were defined as the value closest to the date of start of ART up to 6 months prior.
d
Initial ART regimen was classified as NNRTI-based or PI-based. Integrase inhibitor-based regimens were too few (N = 75) to draw consistent conclusions and were thus excluded.
e
Concurrent AIDS defining illness (ADI) was defined as the presence of any CDC 1993 condition at six months prior to up to one month after start of ART
f
Hepatitis B/C co-infection was defined as having chronic infection at the start of ART.